Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RMTI, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Citrate FDA approved Jan 2015 · Triferic (discontinued) |
Iron-Refractory Iron-Deficiency Anemia | Phase 2 · NCT02905981 | Terminated |
| Triferic AVNU | End Stage Renal Disease | Phase 4 · NCT04689932 | Completed |
| SFP | End Stage Renal Disease | Phase 3 · NCT01503021 | Completed |
| Soluble ferric pyrophosphate | Renal Failure Chronic Requiring Hemodialysis | Phase 3 · NCT01322347 | Completed |
| Triferic | End Stage Renal Disease | Phase 3 · NCT04239391 | Unknown |
| Erythrocyte Stimulating Agent (ESA) | End Stage Renal Disease | Phase 2 · NCT01286012 | Completed |
| Fer-In-Sol | Iron-Refractory Iron-Deficiency Anemia | Phase 2 · NCT02905981 | Terminated |
| Heparin | End Stage Renal Disease | Phase 1/2 · NCT04042324 | Completed |
| Iron | End Stage Renal Disease | Phase 2 · NCT01286012 | Completed |
| Soluble Ferric Pyrophosphate in liquid… | End Stage Renal Disease | Phase 2 · NCT01286012 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RMTI holds $22.5M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RMTI files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Mark H Ravich Director |
Insider | 151,103 | 3.75% | 2025-05-20 |
| Mark Strobeck President and CEO, Director · +352,000 options |
Insider | 61,349 | 1.52% | 2026-10-01 |
| Megan C. Timmins EVP, CLO & Secretary · +97,500 options |
Insider | 31,240 | 0.78% | 2026-07-01 |
| Heather Hunter Chief Operating Officer |
Insider | 28,007 | 0.69% | 2026-07-01 |
| Timothy Chole SVP and CCO · +85,000 options |
Insider | 27,285 | 0.68% | 2026-07-01 |
| Jesse Neri SVP and CFO · +97,500 options |
Insider | 27,239 | 0.68% | 2026-07-01 |
| Robert S Radie Director |
Insider | 23,985 | 0.60% | 2026-07-01 |
| Allen Nissenson Director |
Insider | 23,892 | 0.59% | 2026-07-01 |
| John G Cooper Director |
Insider | 23,670 | 0.59% | 2026-07-01 |
| Joan Lau Director |
Insider | 20,944 | 0.52% | 2026-07-01 |
| Joseph H Dawson Director · +25,000 options |
Insider | 12,133 | 0.30% | 2026-07-01 |
Share count 4,030,465 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RMTI and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →